Skip to main content
Premium Trial:

Request an Annual Quote

GenomeWebinars

Tue
Mar
19
1:00 PM
US Eastern

Sponsored by Agena Bioscience

Panel Talk: Standardizing Pharmacogenomics Laboratory Processes and Reporting

Precision medicine and pharmacogenomics (PGx) have become increasingly critical components of healthcare, but a lack of standardization in clinical laboratory processes and reporting has, up to this point, hindered widespread adoption and implementation.

In this panel discussion, PGx experts Vicky Pratt, past president of AMP and director of scientific affairs for pharmacogenetics at Agena, and Kristine Ashcraft, founder of YouScript, will discuss the current state of PGx standardization and how they see things taking shape for the future by addressing such topics as:

  • Terminology used to characterize metabolizer status.
  • Clinically relevant genes and variants critical for testing.
  • Alignment of supporting evidence from key PGx societies.
  • Structure and requirements of clinical reports.

Sponsored by

Thu
Mar
21
11:00 AM
US Eastern

Sponsored by Qiagen

Advances in Genomic Testing for Rare Disease Diagnostics: Detection, Interpretation, Access

Over the past decade, whole-exome and whole-genome sequencing have transformed the diagnosis of patients with suspected rare genetic diseases. However, despite recent advancements, a large number of patients with rare genetic diseases remains undiagnosed for years because they have limited access to comprehensive genomic testing.

In this virtual roundtable of leading rare disease experts, panelists will discuss:

  • The state of clinical genomic testing at their institutions.
  • How recent advances in sequencing technology and data analysis, including artificial intelligence (AI), are increasing diagnostic rate.
  • How barriers to patient access to testing can be removed to improve the care of all people living with rare genetic diseases.

The panelists on this event are Danny E. Miller, MD, PhD, assistant professor in the Department of Pediatrics, Division of Genetic Medicine at the University of Washington, Vaidehi Jobanputra, PhD, FACMG, associate professor of pathology and cell biology at Columbia University Medical Center, Gilad D. Evrony, MD, PhD, assistant professor, Departments of Pediatrics and Neuroscience and Physiology at NYU School of Medicine and Malte Spielmann, PhD, MD, professor of human genetics at the University Hospital Schleswig-Holstein.

Sponsored by

field_file_image_alt_text_value
Mon
Mar
25
12:00 PM
US Eastern

Sponsored by Porex Filtration Group

Enabling Rapid Point-of-Care Diagnostic Testing Across Varied Sample Types With Porous Plastics

The COVID-19 pandemic highlighted how rapid assays can become a critical part of healthcare, allowing fast and accurate point-of-care results by untrained users. However, the pandemic also highlighted the importance of being able to use a wide variety of sample types to allow for screening, diagnosis, epidemiology, and treatment monitoring.

Porous plastics have emerged as an important tool in the developer’s tool kit, providing a physically robust material that can be used in sample collection, sample treatment, conjugate release, and absorption — in many ways a replacement for more traditional materials like glass fiber or cellulose.

In this webinar, Kevin Jones, chief technology officer of Palladium Diagnostics, will discuss the significance of different sample types for the new generation of rapid diagnostic assays, along with the correct materials to choose and how to optimize the performance using porous plastics in collection and test devices.

Sponsored by

Porex Filtration Group
Tue
Mar
26
1:00 PM
US Eastern

Sponsored by Invitae

Advancing Oncology Treatment With Personalized Molecular Residual Disease Testing

The integration of circulating tumor DNA (ctDNA) detection, shed by malignant tumors, is becoming a standard practice for healthcare providers involved in the care of patients with cancer. The identification of tumor-specific molecular alterations in ctDNA post-definitive cancer treatment can indicate potential disease persistence or recurrence. Bespoke ctDNA assays are a highly sensitive method for detecting minimal (or molecular) residual disease (MRD) utilizing next-generation DNA sequencing. These tests begin with the initial identification of molecular alterations in tumor tissue via whole-exome analysis, followed by the detection of tumor-specific DNA variants in ctDNA. The technology's capability extends beyond merely confirming the presence or absence of ctDNA; it quantifies ctDNA levels, thereby offering insights into changes in tumor burden over time. This feature is particularly beneficial for tracking treatment responses in patients with advanced cancer undergoing systemic therapy.

During this webinar, attendees will learn about the contemporary spectrum of MRD detection methodologies and their practical applications in oncology. The session will include an in-depth exploration of tumor-informed MRD detection technologies, detailing sample requirements and report formatting. Further, the speakers will present findings from recent clinical studies employing these assays, underscoring their prognostic and predictive values. 

Learning Objectives:

  • Review methodologies utilized in developing and validating bespoke panels for ctDNA detection. 
  • Develop an understanding of the potential of MRD assessments for prognostication and early detection of recurrence. 
  • Understand how these assays can support the development of novel cancer therapies, including informing clinical trial design, monitoring therapeutic response, and advancing translational research, with the ultimate goal of improving patient outcomes.

Sponsored by

Wed
Mar
27
1:00 PM
US Eastern

Sponsored by Agena Bioscience

Rethinking Solid Tumor Profiling: How Utilizing Complementary Technologies Can Allow Laboratories to Guide Better Treatment Decisions

Characterizing the genetic profile of lung adenocarcinomas upon initial diagnosis has become a critical step in guiding the management and treatment of patients. The need for the detection of multiple biomarkers in a single, limited diagnostic sample has driven the adoption of two complementary technologies at Houston Methodist Hospital.

In this workshop, Jessica Thomas, assistant professor of clinical pathology and genomic medicine, will share how Methodist delivers significantly accelerated results and a higher success rate for low cellularity samples by supplementing NGS with the MassARRAY platform. She will discuss how this testing paradigm has impacted patients and key considerations for implementation.  

Sponsored by

Thu
Apr
11
1:00 PM
US Eastern

Sponsored by Millipore Sigma

The Increasing Importance of Diagnostics Development and Commercialization Partnerships in the Post-COVID Era

The diagnostics industry has entered a new era. Buffeted by the impacts of the COVID pandemic, challenging access to capital markets, increasing regulatory scrutiny, and continued market access pressure, the development and commercialization of novel diagnostic technology and tests has become increasingly resource intensive. While partnerships have always been a critical approach to fill capability or technology gaps, today they are an increasingly important tool to mitigate complexity and cost challenges. Selection of key suppliers and partners can provide a competitive edge in bringing new diagnostics to market.

In this webinar, Donna Hochberg, head of diagnostics, life science tools and services, and precision medicine at Health Advances, will explore how the landscape for diagnostics development and commercialization has changed in the post-COVID world and discuss the role that partnerships can have in facilitating success across the entire product life cycle. The session will also discuss the shifting motivations of various stakeholders, such as diagnostic innovators, established diagnostics players, biopharma, providers, and CDMOs, and the evolving nature of these partnerships. Cheri Drennan, director of planning and implementation at MilliporeSigma, will discuss how the company can accelerate time to commercialization by providing tailored solutions in reagent customization, assay development, formulation support, and scale-up to manufacturing. Participants in this session will leave with a renewed appreciation for the role of partnerships in enhancing diagnostics innovation by increasing speed, improving quality and success rates, and building successful channel and market access pathways, as well as a perspective on how and when to employ various partnership strategies.

Sponsored by

field_file_image_alt_text_value